Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02437838 · ClinicalTrials.gov registry record

Optimizing Drug Doses in Critically Ill

A clinical trial of Traumatic Brain Injury and Kidney Functional, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
20
Enrollment target
2
Study locations

NCT02437838 is a study of Traumatic Brain Injury and Kidney Functional that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 20 participants, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02437838, a study of Traumatic Brain Injury and Kidney Functional, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
20 participants
Enrollment target
2
Study locations

Study Summary

The primary objectives of this study are to examine whether augmented renal clearance (ARC) compromises renally eliminated drug therapeutic serum concentrations in patients with traumatic brain injury (TBI) and to estimate the optimal dose needed to achieve therapeutic serum concentrations of the probe medication levetiracetam in patients with TBI.

Interventions

  • OTHER No Intervention

Study Locations (2)

Kentucky

  • University of Kentucky - Lexington

North Carolina

  • University of North Carolina at Chapel Hill - Chapel Hill

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2015-08
Est. Completion 2016-08

What the Registry Record Tells You About NCT02437838

The ClinicalTrials.gov registry entry for NCT02437838 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 277-participant average among 171 other Traumatic Brain Injury trials with a reported enrollment target (93% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Traumatic Brain Injury appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.

NCT02437838 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Kentucky, North Carolina.

Frequently Asked Questions

What is clinical trial NCT02437838 about?

NCT02437838 is a clinical study titled "Optimizing Drug Doses in Critically Ill". The primary objectives of this study are to examine whether augmented renal clearance (ARC) compromises renally eliminated drug therapeutic serum concentrations in patients with traumatic brain injury (TBI) and to estimate the optimal dose needed to achieve therapeutic serum concentrations of the pr...

What is the current status of trial NCT02437838?

This trial is currently completed. The enrollment target is 20 participants. The study started on 2015-08. Estimated completion is 2016-08.

What conditions does trial NCT02437838 study?

This clinical trial studies the following conditions: Traumatic Brain Injury, Kidney Functional.

What interventions are being tested in trial NCT02437838?

The interventions under investigation include: No Intervention (OTHER).

Who is sponsoring clinical trial NCT02437838?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02437838 being conducted?

This trial has 2 study locations across Kentucky, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Traumatic Brain Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.